Valeant has been promising a hostile takeover approach for Allergan since the company's board unanimously shot down its $53 billion cash-and-stock bid. And now, it's made its first move.
written on 19.06.2014
Valeant has been promising a hostile takeover approach for Allergan since the company's board unanimously shot down its $53 billion cash-and-stock bid. And now, it's made its first move.
See our Cookie Privacy Policy Here